Edwyn
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | $41,651 | $81,288 | $100,330 | $58,496 | $63,627 |
| Gross Profit | $32,959 | $50,467 | $65,986 | $33,542 | $45,776 |
| Operating Income | N/A | N/A | N/A | N/A | N/A |
| Net Income | $9,616 | $21,979 | $31,372 | $2,119 | $8,031 |
Over the five-year period, Pfizer Inc.’s revenue and gross profit exhibited notable volatility with a clear double-digit growth pattern in the early years followed by a pronounced decline in 2023. Revenue nearly doubled from USD 41.65 billion in 2020 to USD 81.29 billion in 2021 and increased further to USD 100.33 billion in 2022—a significant year-over-year growth exceeding 20% in both 2020–2021 and 2021–2022. This strong upward trend was mirrored by gross profit, which increased from USD 32.96 billion in 2020 to USD 65.99 billion in 2022, suggesting efficient scaling of operations and potentially favorable product or service mix. However, a sharp decline occurred in 2023, where revenue fell to USD 58.50 billion and gross profit declined to USD 33.54 billion. This drop of roughly 41% in revenue compared to 2022 represents the most significant year-over-year swing in the period, possibly reflecting market adjustments or a wind-down of pandemic-related surges that boosted previous figures. Net income trends reinforce this mixed performance narrative. While Pfizer reported steady improvements, with net income growing from USD 9.62 billion in 2020 to USD 31.37 billion in 2022, the figure plummeted to USD 2.12 billion in 2023—a decline far exceeding the 20% threshold, before partially rebounding to USD 8.03 billion in 2024. The operating income remains unreported or non-calculable which limits a comprehensive view of operating efficiency. Overall, while Pfizer’s early period showed robust revenue expansion and profitability, the marked downturn in 2023 followed by a modest recovery emphasizes volatility. Based solely on these metrics, Pfizer appears generally resilient, but the sharp fluctuations call for careful monitoring to ensure long-term financial sustainability in a competitive pharmaceutical market.
This analysis is for informational purposes only and does not constitute financial advice or recommendations for any investment decisions. Please consult with a qualified financial professional for personalized guidance.